What is Nuclein?
Founded in 2017 by biotechnology veterans Alan Blake and Dr. Richard Crockett, Nuclein is dedicated to revolutionizing infectious disease testing. The company's core mission is to develop a portable, disposable, all-in-one self-test device. This innovative solution aims to deliver sample-to-answer results within an hour, directly at the point of care, eliminating the need for laboratory mail-ins. This approach positions Nuclein to significantly impact rapid diagnostics and public health preparedness.
How much funding has Nuclein raised?
Nuclein has raised a total of $19.6M across 2 funding rounds:
Series A
$5.6M
Series B
$14M
Series A (2020): $5.6M, investors not publicly disclosed
Series B (2021): $14M led by Trinity Private Equity Group
Key Investors in Nuclein
Trinity Private Equity Group
Trinity Private Equity Group is a notable investment firm that likely focuses on providing significant capital to companies with strong growth potential, particularly within the healthcare and technology sectors.
What's next for Nuclein?
The recent major strategic investment signals a critical growth phase for Nuclein, likely enabling the company to scale its operations, accelerate product development, and expand its market reach. This infusion of capital is expected to facilitate the final stages of bringing its groundbreaking infectious disease self-test to market, potentially transforming how individuals and healthcare providers manage and detect infections. The company's focus on rapid, accessible diagnostics aligns with increasing global demand for efficient healthcare solutions.
See full Nuclein company page
